News

Karen B. DeSalvo, National Coordinator for Health Information Technology, gives the best courses of action for top technology challenges and opportunities facing healthcare executives.

A new Quest Diagnostics and Inovalon study cites barriers to value-based care, but offers advice on how to overcome them.

As asthma prevalence continues to rise in the adult and pediatric populations, U.S. healthcare spending on medications, especially branded inhalers, is expected to increase.

Express Scripts Exchange Pulse report found that utilization, particularly for traditional meds, was one of the biggest factors driving spending in 2015, accounting for more than half of the exchange plans $99 PMPY increase in spending between 2014 and 2015.

CMS finalized new rules that aim to enrich the Qualified Entity Program by expanding access to analyses and data that will help providers, employers, and others make more informed decisions about care delivery and quality improvement.

All antibiotic use has the potential to contribute to the development of antibiotic resistance. That’s why it is key to reduce inappropriate antibiotic use in order to slow the growth of resistance.

Health plans must find new and meaningful ways to connect with patients of diverse backgrounds.

Remote monitoring studies are missing the mark when assessing the value of the technology. Here’s why.

Is digital health integration the missing link in understanding chronic diseases and what should physicians be asking to ensure the data they want to receive is captured effectively?

Payers pair with providers to manage patients with chronic disease at a distance.

Many health systems have a hard time capturing and using data from patients that can make a real impact on their businesses. Here are some innovative projects to have on your radar.

Cyberattacks based on ransomware-hacking into a computer system and holding it hostage until the victim pays to regain access-are on the rise.

Multiple factors are moving mental healthcare to a front burner issue in managed care.

In an era when adherence to specialty pharmaceuticals is disturbingly low, value-based pricing needs real-world results, not single-arm accelerated trials.

A new drug approved by FDA to treat chronic hepatitis C virus (HCV) infection this week enters a competitive, lucrative market headed up by Gilead Science’s Sovaldi and Harvoni, as well as AbbVie’s Viekira Pak. FDA granted priority review and breakthrough therapy designation to Gilead’s combination product, Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg).

Health plans have found that Affordable Care Act (ACA) exchange plans are plagued with loopholes, and that some consumers are taking advantage.

Study seeks to determine whether significant improvement in glycemic control can be achieved when regular coaching is part of the process.

Empowerment is an important factor to address everyday aspects of dealing with a chronic disease, including diabetes, according to a study that evaluated the effect of diabetes empowerment on medication adherence and self-care behaviors in adults with type 2 diabetes.

The U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) plans to help bring a vaccine for the Zika virus to market immediately via Emergent BioSolutions Inc., which also developed the anthrax vaccine.

Is the republican alternative ACA plan a viable trade-off? Here are some key elements of the plan to consider.

We recently asked experts to define the top challenges associated with diabetes health management, and how health plans can overcome them.

As health systems and physician groups marshal resources to launch their own plans, they must consider whether they have the necessary building blocks to successfully make the leap, how integrated a model they will pursue and whether they will build, buy or partner strategy.

Timely and broad use of Entresto could prevent or postpone more than 28,000 US deaths per year among HFrEF patients, according to research in JAMA Cardiology.

FDA recently granted accelerated approval for obeticholic acid (Ocaliva, Intercept Pharmaceuticals, Inc.) for the treatment of primary biliary cholangitis.

It is important to look at how the introduction of biosimilars in the United States may affect your business and your stakeholders and plan for those changes accordingly, according to a new report.

What impact will MACRA have on your organization? We asked experts to tell us.

A new PwC Health Research Institute report notes that while strides are being made in population health, many organizations struggle to scale efforts.

FDA just granted Breakthrough Therapy Designation for the first treatment for acute graft-versus-host disease (GVHD): ruxolitinib (Jakafi, Incyte Corp.).

The first-year results of the ACA’s Risk Adjustment Program are in. Find out how it worked out and what insurers need to do next.

Boosting patient engagement is critical as the industry shifts toward value-based payments. For payers and providers, higher engagement increases the likelihood of positive outcomes at lower costs.